Literature DB >> 8478091

A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis.

Z P Yang1, C C Kuo, J T Grayston.   

Abstract

Chlamydia pneumoniae is a common cause of acute respiratory infections in humans. We evaluated mice as experimental animals for C. pneumoniae. Intranasal inoculation of Swiss Webster mice with C. pneumoniae induced a prolonged course of lung infection, as demonstrated by reisolation of organisms from lungs (at 42 days) and persistence of lung pathology (> 60 days). The lung pathology was characterized by patchy interstitial pneumonitis with predominantly polymorphonuclear leukocyte infiltration in the early and mononuclear cell infiltration in the later stages of infection. Inoculated mice developed serum immunoglobulin G antibody responses and partial resistance against rechallenge inoculation. The other mouse strains tested, Icr, BALB/cAnN, C57BL/6N, C3H/HeN, and B6C3F1, were shown to be susceptible to C. pneumoniae. The mouse model should be useful for investigating the immunopathogenesis of C. pneumoniae infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478091      PMCID: PMC280800          DOI: 10.1128/iai.61.5.2037-2040.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

Review 1.  Infections caused by Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

2.  Identification of a new group of Chlamydia psittaci strains called TWAR.

Authors:  C C Kuo; H H Chen; S P Wang; J T Grayston
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

3.  Inapparent respiratory infection of inbred Swiss mice with sulfadiazine-resistant, iodine-negative Chlamydiae.

Authors:  F A Ata; E H Stephenson; J Storz
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

4.  A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR.

Authors:  C C Kuo; J T Grayston
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

5.  A mouse model of pneumonitis induced by Chlamydia trachomatis: morphologic, microbiologic, and immunologic studies.

Authors:  W Chen; C Kuo
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

6.  Chlamydia pneumoniae elementary body antigenic reactivity with fluorescent antibody is destroyed by methanol.

Authors:  S P Wang; J T Grayston
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

7.  A mouse model of Chlamydia trachomatis pneumonitis.

Authors:  C Kuo; W J Chen
Journal:  J Infect Dis       Date:  1980-02       Impact factor: 5.226

8.  Chlamydia trachomatis pneumonitis in the C57BL/KsJ mouse: pathologic and immunologic features.

Authors:  H R Harrison; S M Lee; D O Lucas
Journal:  J Lab Clin Med       Date:  1982-12

9.  Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques.

Authors:  A Shor; C C Kuo; D L Patton
Journal:  S Afr Med J       Date:  1992-09

10.  Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979.

Authors:  M B Aldous; J T Grayston; S P Wang; H M Foy
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

View more
  27 in total

1.  Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods.

Authors:  A Meijer; P J Roholl; S K Gielis-Proper; Y F Meulenberg; J M Ossewaarde
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

2.  Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge.

Authors:  J M Vuola; V Puurula; M Anttila; P H Mäkelä; N Rautonen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Development of a hamster model of Chlamydophila pneumoniae infection.

Authors:  A Marangoni; V Sambri; M Donati; K Di Leo; R Cevenini
Journal:  Vet Res Commun       Date:  2005-03       Impact factor: 2.459

4.  Development of diabetes in non-obese diabetic mice promotes Chlamydia pneumoniae dissemination from lung to peripheral blood.

Authors:  Hiroyuki Yamaguchi; Ichiro Oshio; Takako Osaki; Satoru Kurata; Yoshimasa Yamamoto; Shigeru Kamiya
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

Review 5.  Infection and Atherosclerosis Development.

Authors:  Lee Ann Campbell; Michael E Rosenfeld
Journal:  Arch Med Res       Date:  2015-05-21       Impact factor: 2.235

6.  Type 1 T-cell responses in chlamydial lung infections are associated with local MIP-1alpha response.

Authors:  Naihong Zhang; Zhaoe Wang; Xiaofei Tang; Haiping Wang; Hongzhao Li; Huanjun Huang; Hong Bai; Xi Yang
Journal:  Cell Mol Immunol       Date:  2010-07-12       Impact factor: 11.530

7.  Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model.

Authors:  Ulla Airaksinen; Tuula Penttilä; Eva Wahlström; Jenni M Vuola; Mirja Puolakkainen; Matti Sarvas
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

8.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

10.  The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection.

Authors:  Kenichi Shimada; Shuang Chen; Paul W Dempsey; Rosalinda Sorrentino; Randa Alsabeh; Anatoly V Slepenkin; Ellena Peterson; Terence M Doherty; David Underhill; Timothy R Crother; Moshe Arditi
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.